<p>Adverse reactions, sometimes severe and life-threatening or fatal, have been seen in clinical trials with Aflibercept, including:</p>

<ul>
	<li>Fistula Formation: Discontinue Aflibercept if fistula occurs.</li>
	<li>Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Aflibercept if hypertension is not controlled. Discontinue Aflibercept if hypertensive crisis develops.</li>
	<li>Arterial Thromboembolic Events (ATE) (e.g., transient ischemic attacks, cerebrovascular accident, angina pectoris): Discontinue Aflibercept if ATE develops.</li>
	<li>Proteinuria: Monitor urine protein. Suspend Aflibercept when proteinuria &ge; 2 grams per 24 hours. Discontinue Aflibercept if nephrotic syndrome or thrombotic microangiopathy (TMA) develops.</li>
	<li>Neutropenia and Neutropenic Complications: Delay administration of Aflibercept/FOLFIRI until neutrophil count is &ge; 1.5 &times; 109/L.</li>
	<li>Diarrhea and Dehydration: Incidence of severe diarrhea and dehydration is increased. Monitor elderly patients more closely.</li>
	<li>Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue Aflibercept.</li>
</ul>